PRISM: a novel research tool to assess the prevalence of pseudobulbar affect symptoms across neurological conditions.

<h4>Background</h4>Pseudobulbar affect (PBA) is a neurological condition characterized by involuntary, sudden, and frequent episodes of laughing and/or crying, which can be socially disabling. Although PBA occurs secondary to many neurological conditions, with an estimated United States...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Benjamin Rix Brooks, David Crumpacker, Jonathan Fellus, Daniel Kantor, Randall E Kaye
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2013
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/9a8f8d25173843b8b589297258b8335c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9a8f8d25173843b8b589297258b8335c
record_format	dspace
spelling	oai:doaj.org-article:9a8f8d25173843b8b589297258b8335c2021-11-18T08:58:34ZPRISM: a novel research tool to assess the prevalence of pseudobulbar affect symptoms across neurological conditions.1932-620310.1371/journal.pone.0072232https://doaj.org/article/9a8f8d25173843b8b589297258b8335c2013-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23991068/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4>Pseudobulbar affect (PBA) is a neurological condition characterized by involuntary, sudden, and frequent episodes of laughing and/or crying, which can be socially disabling. Although PBA occurs secondary to many neurological conditions, with an estimated United States (US) prevalence of up to 2 million persons, it is thought to be under-recognized and undertreated. The PBA Registry Series (PRISM) was established to provide additional PBA symptom prevalence data in a large, representative US sample of patients with neurological conditions known to be associated with PBA.<h4>Methods</h4>Participating clinicians were asked to enroll ≥20 consenting patients with any of 6 conditions: Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), Parkinson's disease (PD), stroke, or traumatic brain injury (TBI). Patients (or their caregivers) completed the Center for Neurologic Study-Lability Scale (CNS-LS) and an 11-point scale measuring impact of the neurological condition on the patient's quality of life (QOL). Presence of PBA symptoms was defined as a CNS-LS score ≥13. Demographic data and current use of antidepressant or antipsychotic medications were also recorded.<h4>Results</h4>PRISM enrolled 5290 patients. More than one third of patients (n = 1944; 36.7%) had a CNS-LS score ≥13, suggesting PBA symptoms. The mean (SD) score measuring impact of neurological condition on QOL was significantly higher (worse) in patients with CNS-LS ≥13 vs <13 (6.7 [2.5] vs. 4.7 [3.1], respectively; P<0.0001 two-sample t-test). A greater percentage of patients with CNS-LS ≥13 versus <13 were using antidepressant/antipsychotic medications (53.0% vs 35.4%, respectively; P<0.0001, chi-square test).<h4>Conclusions</h4>Data from PRISM, the largest clinic-based study to assess PBA symptom prevalence, showed that PBA symptoms were common among patients with diverse neurological conditions. Higher CNS-LS scores were associated with impaired QOL and greater use of antipsychotic/antidepressant medications. These data underscore a need for greater awareness, recognition, and diagnosis of PBA.Benjamin Rix BrooksDavid CrumpackerJonathan FellusDaniel KantorRandall E KayePublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 8, Iss 8, p e72232 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Benjamin Rix Brooks David Crumpacker Jonathan Fellus Daniel Kantor Randall E Kaye PRISM: a novel research tool to assess the prevalence of pseudobulbar affect symptoms across neurological conditions.
description	<h4>Background</h4>Pseudobulbar affect (PBA) is a neurological condition characterized by involuntary, sudden, and frequent episodes of laughing and/or crying, which can be socially disabling. Although PBA occurs secondary to many neurological conditions, with an estimated United States (US) prevalence of up to 2 million persons, it is thought to be under-recognized and undertreated. The PBA Registry Series (PRISM) was established to provide additional PBA symptom prevalence data in a large, representative US sample of patients with neurological conditions known to be associated with PBA.<h4>Methods</h4>Participating clinicians were asked to enroll ≥20 consenting patients with any of 6 conditions: Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), Parkinson's disease (PD), stroke, or traumatic brain injury (TBI). Patients (or their caregivers) completed the Center for Neurologic Study-Lability Scale (CNS-LS) and an 11-point scale measuring impact of the neurological condition on the patient's quality of life (QOL). Presence of PBA symptoms was defined as a CNS-LS score ≥13. Demographic data and current use of antidepressant or antipsychotic medications were also recorded.<h4>Results</h4>PRISM enrolled 5290 patients. More than one third of patients (n = 1944; 36.7%) had a CNS-LS score ≥13, suggesting PBA symptoms. The mean (SD) score measuring impact of neurological condition on QOL was significantly higher (worse) in patients with CNS-LS ≥13 vs <13 (6.7 [2.5] vs. 4.7 [3.1], respectively; P<0.0001 two-sample t-test). A greater percentage of patients with CNS-LS ≥13 versus <13 were using antidepressant/antipsychotic medications (53.0% vs 35.4%, respectively; P<0.0001, chi-square test).<h4>Conclusions</h4>Data from PRISM, the largest clinic-based study to assess PBA symptom prevalence, showed that PBA symptoms were common among patients with diverse neurological conditions. Higher CNS-LS scores were associated with impaired QOL and greater use of antipsychotic/antidepressant medications. These data underscore a need for greater awareness, recognition, and diagnosis of PBA.
format	article
author	Benjamin Rix Brooks David Crumpacker Jonathan Fellus Daniel Kantor Randall E Kaye
author_facet	Benjamin Rix Brooks David Crumpacker Jonathan Fellus Daniel Kantor Randall E Kaye
author_sort	Benjamin Rix Brooks
title	PRISM: a novel research tool to assess the prevalence of pseudobulbar affect symptoms across neurological conditions.
title_short	PRISM: a novel research tool to assess the prevalence of pseudobulbar affect symptoms across neurological conditions.
title_full	PRISM: a novel research tool to assess the prevalence of pseudobulbar affect symptoms across neurological conditions.
title_fullStr	PRISM: a novel research tool to assess the prevalence of pseudobulbar affect symptoms across neurological conditions.
title_full_unstemmed	PRISM: a novel research tool to assess the prevalence of pseudobulbar affect symptoms across neurological conditions.
title_sort	prism: a novel research tool to assess the prevalence of pseudobulbar affect symptoms across neurological conditions.
publisher	Public Library of Science (PLoS)
publishDate	2013
url	https://doaj.org/article/9a8f8d25173843b8b589297258b8335c
work_keys_str_mv	AT benjaminrixbrooks prismanovelresearchtooltoassesstheprevalenceofpseudobulbaraffectsymptomsacrossneurologicalconditions AT davidcrumpacker prismanovelresearchtooltoassesstheprevalenceofpseudobulbaraffectsymptomsacrossneurologicalconditions AT jonathanfellus prismanovelresearchtooltoassesstheprevalenceofpseudobulbaraffectsymptomsacrossneurologicalconditions AT danielkantor prismanovelresearchtooltoassesstheprevalenceofpseudobulbaraffectsymptomsacrossneurologicalconditions AT randallekaye prismanovelresearchtooltoassesstheprevalenceofpseudobulbaraffectsymptomsacrossneurologicalconditions
_version_	1718421099092377600

PRISM: a novel research tool to assess the prevalence of pseudobulbar affect symptoms across neurological conditions.

Ejemplares similares